GlassScriptPhysician profile
Simon J Hong
NPI 1740684455
$99,037.68
in general payments reported to CMS, 2019-2025
18 companies · $3,621 in 2025
The $3,621 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $40K · 2021: $1,307 · 2022: $3,191 · 2023: $9,260 · 2024: $1,446 · 2025: $3,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,225 · Food and Beverage: $5,053 · Education: $48.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,225.00 |
| Food and Beverage | $5,052.56 |
| Education | $48.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $80,676.91 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $8,462.45 | 2021-2023 | |
| Abbvie INC. | $4,314.29 | 2020-2025 | |
| Janssen Biotech, INC. | $2,473.81 | 2021-2025 | Tremfya, Stelara |
| Celgene Corporation | $1,072.33 | 2019-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $867.16 | 2021-2025 | Entyvio, Gattex |
| Ferring Pharmaceuticals INC. | $243.12 | 2022-2024 | Rebyota |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.46 | 2021-2024 | Xifaxan |
| Organon LLC | $144.53 | 2022-2024 | Renflexis, Hadlima |
| Regeneron Pharmaceuticals, INC. | $138.14 | 2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $137.66 | 2019 | |
| Nestle Healthcare Nutrition INC. | $131.04 | 2021-2022 | |
| Daiichi Sankyo INC. | $62.43 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $31.82 | 2025 | Vowst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.94 | 2024 | Cyltezo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $21.18 | 2025 | Hyrimoz |
| Lilly USA, LLC | $20.39 | 2024 | Omvoh |
| Amgen INC. | $15.02 | 2023 | Amjevita, Avsola |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Hong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.